Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (Q4967095)

From MaRDI portal
scientific article; zbMATH DE number 7075686
Language Label Description Also known as
English
Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents
scientific article; zbMATH DE number 7075686

    Statements

    Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents (English)
    0 references
    0 references
    0 references
    0 references
    2 July 2019
    0 references
    attributable toxicity
    0 references
    cancer phase I trials
    0 references
    continual reassessment method
    0 references
    copula type models
    0 references
    drug combination
    0 references

    Identifiers

    0 references
    0 references
    0 references
    0 references
    0 references
    0 references
    0 references